SK Bioscience Co Ltd is a pharmaceutical company based in South Korea, specializing in the manufacturing and development of vaccines. They have a medium ESG score of 23.2 and have registered innovative vaccines such as SKYCellflu and 13-valent Pneumococcal Conjugate Vaccine. The company is continuously working on developing new vaccines, including a recombinant rotavirus vaccine and typhoid conjugate vaccine, in collaboration with external partners.